How Do You Lower Familial High Cholesterol? (TRT Q&As)
Timeline
Diet and exercise remain important, but inherited cholesterol problems may also require medication. Dr. O’Connor points to statins and PCSK9 inhibitors as treatment options depending on the individual’s lipid profile and cardiovascular risk.
GLP-1 medications can be effective for weight loss, but appetite suppression, nausea, and vomiting can make them difficult for some people to tolerate. For this 55-year-old already using TRT and several medications, Dr. O’Connor recommends carefully weighing those effects and also considering metabolic health and the ABCDs.
Telmisartan is an ARB, and Dr. O’Connor notes evidence favoring ARBs over ACE inhibitors in some situations. He also highlights potential benefits involving testosterone-related erythrocytosis, LDL cholesterol, and insulin resistance while stressing that the difference is not necessarily dramatic for every patient.
Rather than simply replacing one calcium-channel blocker with another, Dr. O’Connor would look more broadly at the hypertension regimen, lifestyle, testosterone dose, and possible secondary causes. He discusses telmisartan, Bystolic, and sometimes hydrochlorothiazide as options that could be reviewed with the treating physician.
Low ferritin can develop as testosterone increases red blood cell production, particularly when repeated phlebotomies further deplete iron. Dr. O’Connor emphasizes balancing hemoglobin, hematocrit, ferritin, transferrin saturation, testosterone dose, and other contributors rather than automatically adding iron or repeatedly donating blood.
Video Summary
The mailbag discussion responds to common questions surrounding testosterone therapy and how symptoms should be interpreted alongside laboratory data. It emphasizes avoiding reactive protocol changes driven by single lab values or short-term fluctuations. Clinical context is reinforced as central to safe decision-making.
Several questions focus on laboratory interpretation, including why values may shift despite stable therapy. The episode explains how timing, variability, and individual physiology influence results. Trend-based evaluation is emphasized over isolated numbers.
The closing portion integrates testosterone therapy into long-term clinical care. Ongoing monitoring, individualized reassessment, and risk awareness are highlighted. Hormone therapy is framed as an evolving process rather than a static intervention.
Drug Callouts
Condition Callouts
Key Takeaways
- Mailbag questions highlight common areas of confusion about testosterone therapy.
- Laboratory context is essential when interpreting results.
- Symptoms should be evaluated alongside lab trends.
- Reactive protocol changes can introduce unnecessary risk.
- Long-term monitoring supports safer hormone management.